Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Immunovia announces updated financial calendar

April 22, 2024

LUND (SWEDEN) Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024.

 
 

Annual Report to be published April 29, 2024
Q1 Report, 2024 April 29, 2024
Annual General Meeting June 4, 2024
Q2 Report, 2024 August 22, 2024
Q3 Report, 2024 November 14, 2024

 

 
 

For more information, please contact:

Karin Almqvist Liwendahl

Chief Financial Officer

karin.almqvist.liwendahl@immunovia.com

+46 709 11 56 08

 

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

 

USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

 

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visitwww.immunovia.com